News

Johnson & Johnson's stock recently experienced a slight setback, declining 1.14 percent to $162.38 amid challenging market conditions. However, the pharmaceutical giant's long-term outlook appears

Quest Diagnostics, a leading provider of diagnostic information services, experienced a significant 4.75% decline on the New York Stock Exchange following disappointing long-term growth projections

Pharmaceutical giant Pfizer has divested its complete shareholding in consumer health company Haleon for approximately £2.5 billion ($3.24 billion). The transaction was executed at 385 pence per

Eli Lilly faces a potential challenge to its dominant position in the lucrative GLP-1 market after Lexaria Bioscience Corp. reported breakthrough results with its oral DehydraTECH-tirzepatide

Incyte Corporation is poised for significant market growth following positive results from two pivotal Phase 3 trials for Povorcitinib, its oral JAK1 inhibitor targeting Hidradenitis suppurativa

Die Teleflex Aktie verzeichnete am vergangenen Freitag einen moderaten Anstieg von 0,80% und erreichte damit einen Kurs von 126,50 EUR. Diese positive Entwicklung steht im Kontrast zur schwachen

Eli Lilly's stock is facing pressure following a strategic partnership announcement between Swiss pharmaceutical giant Roche and Danish firm Zealand Pharma. The deal, valued at up to $5.3 billion

Healthcare giant Johnson & Johnson is demonstrating remarkable resilience in a volatile market environment. Currently trading at $165.68, the stock has established itself as a defensive asset

Merck, known internationally as MSD, has significantly strengthened its position in the American market with the opening of a new vaccine production facility in Durham, North Carolina. The

Pfizer's stock fell 1.7% to $26.20 in Tuesday afternoon trading on the New York Stock Exchange, despite the company announcing promising results from a key clinical trial. The decline came amid

Bristol-Myers Squibb has announced a definitive agreement to acquire biotechnology company 2seventy bio for $5.00 per share in an all-cash transaction. The deal values 2seventy bio at approximately

Align Technology, a digital dentistry leader valued at $12.1 billion, has announced the European Union and UK launch of its AI-powered "Align X-ray Insights" diagnostic software. The cloud-based

Johnson & Johnson's stock could receive significant momentum following positive developments in multiple therapeutic areas. The company recently secured approval from Health Canada for a combination

Eli Lilly has reported significant progress with its medication Ebglyss for moderate to severe atopic dermatitis. At the American Academy of Dermatology annual meeting in Orlando, the company

Pfizer's stock currently faces a challenging market position, trading precariously close to its 52-week lows. The shares recently showed minimal recovery, rising just 0.2 percent to $25.99 in New

Pfizer shares gained 0.9 percent on Wednesday in New York trading, closing at $25.98 after reaching an intraday high of $26.17. Investor interest remained strong with over one million shares

Abbott Laboratories is experiencing notable stock market activity as multiple senior executives recently divested portions of their holdings. Former Executive Vice President Andrea F. Wainer sold

Vertex Pharmaceuticals Inc. has seen significant insider selling activity recently, with top executives divesting substantial shareholdings while the company's stock enjoys impressive performance

Pharmaceutical giant Eli Lilly and Company, now the world's most valuable pharma corporation with a market capitalization exceeding $855 billion, announced Wednesday it will invest an additional $27

Morgan Stanley's optimistic outlook for Gilead Sciences' HIV prevention medication Lenacapavir has positioned the company for significant market advancement. The drug, anticipated to receive FDA